Trevena, Inc., a biopharmaceutical company, develops therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. Its product candidates include OLINVO injection, a G protein biased ligand of the µ opioid receptor that has completed Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is preferred; TRV250, a G protein biased ligand targeting the d-receptor, which is in Phase I clinical study for the treatment of migraine; and TRV734, a small molecule G protein biased ligand of the µ opioid receptor that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain, as well as TRV027 for the treatment of acute heart failure. The company was founded in 2007 and is headquartered in Chesterbrook, Pennsylvania.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone610-354-8840
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.75 million
Profitability
Miscellaneous
Employees51
OptionableOptionable
Trevena (NASDAQ:TRVN) Frequently Asked Questions
What is Trevena's stock symbol?
Trevena trades on the NASDAQ under the ticker symbol "TRVN."
How were Trevena's earnings last quarter?
Trevena Inc (NASDAQ:TRVN) issued its earnings results on Thursday, November, 8th. The biopharmaceutical company reported ($0.06) EPS for the quarter, topping the Zacks' consensus estimate of ($0.13) by $0.07. The biopharmaceutical company had revenue of $3 million for the quarter, compared to analysts' expectations of $3 million. View Trevena's Earnings History.
When is Trevena's next earnings date?
What price target have analysts set for TRVN?
6 brokers have issued 12-month price targets for Trevena's stock. Their forecasts range from $0.75 to $15.00. On average, they expect Trevena's share price to reach $6.35 in the next twelve months. This suggests a possible upside of 1,060.5% from the stock's current price. View Analyst Price Targets for Trevena.
What is the consensus analysts' recommendation for Trevena?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trevena in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Trevena.
Has Trevena been receiving favorable news coverage?
News headlines about TRVN stock have trended somewhat positive recently, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Trevena earned a coverage optimism score of 1.7 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days.
Are investors shorting Trevena?
Trevena saw a decline in short interest in December. As of December 14th, there was short interest totalling 5,528,864 shares, a decline of 23.3% from the November 30th total of 7,205,280 shares. Based on an average daily trading volume, of 905,772 shares, the short-interest ratio is presently 6.1 days. Currently, 8.2% of the shares of the company are short sold. View Trevena's Current Options Chain.
Who are some of Trevena's key competitors?
Some companies that are related to Trevena include Synlogic (SYBX), Aptinyx (APTX), Zafgen (ZFGN), VBI Vaccines (VBIV), Calithera Biosciences (CALA), Tocagen (TOCA), Recro Pharma (REPH), ProMetic Life Sciences (PFSCF), Molecular Templates (MTEM), Ocular Therapeutix (OCUL), Constellation Pharmaceuticals (CNST), Nature's Sunshine Products (NATR), AcelRx Pharmaceuticals (ACRX), Syndax Pharmaceuticals (SNDX) and CytoDyn (CYDY).
Who are Trevena's key executives?
Trevena's management team includes the folowing people:
- Ms. Carrie L. Bourdow, CEO, Pres & Director (Age 55)
- Dr. Howard A. Rockman M.D., Scientific Founder, Consultant and Member of Scientific Advisory Board
- Mr. John M. Limongelli, Chief Admin. Officer, Sr. VP, Gen. Counsel & Corp. Sec. (Age 48)
- Erin Clark, Sr. Director of Corp. Strategy & Investor Relations
- Mr. Michael Catalano, VP of Marketing
Who are Trevena's major shareholders?
Which major investors are buying Trevena stock?
How do I buy shares of Trevena?
Shares of TRVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Trevena's stock price today?
One share of TRVN stock can currently be purchased for approximately $0.5472.
How big of a company is Trevena?
Trevena has a market capitalization of $45.69 million and generates $3.75 million in revenue each year. The biopharmaceutical company earns $-71,860,000.00 in net income (profit) each year or ($1.21) on an earnings per share basis. Trevena employs 51 workers across the globe.
What is Trevena's official website?
How can I contact Trevena?
Trevena's mailing address is 955 Chesterbrook Boulevard Suite 110, Chesterbrook PA, 19087. The biopharmaceutical company can be reached via phone at 610-354-8840 or via email at [email protected]
MarketBeat Community Rating for Trevena (NASDAQ TRVN)
MarketBeat's community ratings are surveys of what our community members think about Trevena and other stocks. Vote "Outperform" if you believe TRVN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TRVN will underperform the S&P 500 over the long term. You may vote once every thirty days.
